What are the recommended dosing, administration guidelines, monitoring parameters, contraindications, and adverse effects for intravenous L‑arginine infusion?

Intravenous L-Arginine Infusion: Clinical Overview

L-arginine IV infusion is primarily used for two distinct clinical indications: growth hormone stimulation testing (diagnostic) and hyperammonemia management in urea cycle disorders (therapeutic), with markedly different dosing protocols for each indication.

FDA-Approved Diagnostic Use: Growth Hormone Testing

Dosing and Administration

For growth hormone reserve testing, the FDA-approved dosing is:

• Adults and pediatric patients ≥60 kg: 30 g arginine hydrochloride (300 mL of R-Gene® 10) infused over 30 minutes 1
• Pediatric patients <59 kg: 0.5 g/kg arginine hydrochloride (5 mL/kg of R-Gene® 10) infused over 30 minutes, maximum 30 g 1

Critical Administration Guidelines

R-Gene® 10 is a hypertonic solution requiring specific precautions:

• Must be infused through an indwelling needle or soft catheter in an antecubital or suitable vein 1
• For pediatric patients ≤59 kg, the weight-based dose must be withdrawn and placed in a separate container to prevent inadvertent overdose from the 300 mL commercial container 1
• Patients should be at bed rest for ≥30 minutes before infusion begins 1
• Test should be performed in the morning following overnight fast 1

Monitoring Parameters for GH Testing

Blood samples should be drawn at: -30,0,30,60,90,120, and 150 minutes from the contralateral arm 1

Therapeutic Use: Hyperammonemia in Urea Cycle Disorders

Dosing Based on Specific Enzyme Deficiency

The 2020 consensus guidelines provide disease-specific dosing for hyperammonemia management:

For patients <20 kg:

• OTC and CPS deficiencies: 200 mg/kg given over 90 minutes as bolus, then maintenance over 24 hours 2
• ASS and ASL deficiencies: 600 mg/kg given over 90 minutes as bolus, then maintenance over 24 hours 2

For patients >20 kg:

• OTC and CPS deficiencies: 4 g/m² given over 90 minutes as bolus, then maintenance over 24 hours 2
• ASS and ASL deficiencies: 12 g/m² given over 90 minutes as bolus, then maintenance over 24 hours 2

Critical Safety Consideration

Arginine can cause hypotension, particularly in patients simultaneously receiving hemodialysis 2. The dose may need titration or reduction in this setting. This is a crucial pitfall to avoid, as these critically ill patients with hyperammonemia often require concurrent dialysis.

Hemodynamic Effects and Adverse Events

Cardiovascular Effects

Research demonstrates dose-dependent hemodynamic changes:

• At 30 g IV over 30 minutes: Mean arterial pressure decreased by 4.4%, total peripheral resistance decreased by 10.4%, with corresponding increases in heart rate 3
• Dose-response relationship exists: Higher doses correlate with greater decreases in systolic and diastolic blood pressure 4
• At 12 g dose in malaria patients: Mean maximum decrease in MAP was only 6 mmHg (range 0-11), considered clinically insignificant 4

Metabolic Effects

Dose-dependent metabolic changes include:

• Potassium: Mean maximal increase of 0.5 mmol/L at 12 g dose (range 0.2-0.7) 4
• Bicarbonate: Mean maximal decrease of 3 mEq/L at 12 g dose (range 1-7) without significant pH change 4
• These changes were not clinically significant at doses up to 12 g 4

Local Adverse Effects

Mild discomfort at the IV cannula site may occur, attributed to the hypertonic nature of the solution 4

Contraindications and Precautions

Key Contraindications

Avoid chronic L-arginine supplementation in:

• Patients with advanced cardiovascular disease (randomized trials showed increased mortality and worsening endothelial function) 5
• This applies to chronic oral supplementation; acute IV use for diagnostic or hyperammonemia management follows different risk-benefit considerations

Monitoring Requirements

During infusion, monitor:

• Blood pressure and heart rate continuously
• Serum potassium and bicarbonate levels, particularly at higher doses
• IV site for infiltration (hypertonic solution)
• In hyperammonemia: ammonia levels at 2 hours post-initiation 2

Mechanism and Pharmacokinetics

L-arginine serves as the substrate for endothelial nitric oxide synthase (eNOS), producing NO which:

• Induces vasodilation via cyclic GMP formation 3, 6
• Inhibits platelet aggregation 6
• Increases urinary nitrate and cGMP excretion by 97% and 66% respectively at 30 g dose 3

Pharmacokinetic parameters after 30 g IV:

• Peak plasma levels: 6223 ± 407 μmol/L 3
• Clearance: 544 ± 24 mL/min 3
• Elimination half-life: 41.6 ± 2.3 minutes 3
• Onset and duration of vasodilator effects closely correspond to plasma concentration half-life 3

Clinical Pearls and Pitfalls

Common pitfalls to avoid:

1. Dosing errors in pediatrics: Always withdraw weight-based doses for children <59 kg into separate containers to prevent administering the full 300 mL bottle 1

2. Hypotension in dialysis patients: Arginine-induced vasodilation is additive with dialysis-related hypotension; consider dose reduction 2

3. Wrong indication dosing: Do not confuse GH testing doses (30 g over 30 min) with hyperammonemia doses (varies by enzyme deficiency and weight) 2, 1

4. Ignoring enzyme-specific dosing: ASS and ASL deficiencies require 3-fold higher doses than OTC and CPS deficiencies due to different metabolic requirements 2